PHF6 recruits BPTF to promote HIF-dependent pathway and progression in YAP-high breast cancer

[1]  M. Nikiforov,et al.  PHF10 subunit of PBAF complex mediates transcriptional activation by MYC , 2021, Oncogene.

[2]  S. Rocha,et al.  Von Hippel–Lindau (VHL) small-molecule inhibitor binding increases stability and intracellular levels of VHL protein , 2021, The Journal of biological chemistry.

[3]  Zhixian He,et al.  SEC61G promotes breast cancer development and metastasis via modulating glycolysis and is transcriptionally regulated by E2F1 , 2021, Cell Death & Disease.

[4]  G. Semenza,et al.  Hypoxia-inducible factor-dependent ADAM12 expression mediates breast cancer invasion and metastasis , 2021, Proceedings of the National Academy of Sciences.

[5]  A. Brenner,et al.  First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors , 2021, EClinicalMedicine.

[6]  Jianmin Zhang,et al.  Hippo signalling maintains ER expression and ER+ breast cancer growth , 2021, Nature.

[7]  P. Romitti,et al.  Epidemiology of De Novo Metastatic Breast Cancer. , 2021, Clinical breast cancer.

[8]  Yan Shen,et al.  Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma , 2021, Theranostics.

[9]  D. McMillan,et al.  The relationship between hypoxia-inducible factor 1α (HIF-1α) and patient survival in breast cancer: systematic review and meta-analysis. , 2021, Critical reviews in oncology/hematology.

[10]  Hassan Yousefi,et al.  Understanding the role of integrins in breast cancer invasion, metastasis, angiogenesis, and drug resistance , 2021, Oncogene.

[11]  R. Gillies,et al.  The harsh microenvironment in early breast cancer selects for a Warburg phenotype , 2020, Proceedings of the National Academy of Sciences.

[12]  J. Rathmell,et al.  Selective glutamine metabolism inhibition in tumor cells improves anti-tumor T lymphocyte activity in triple-negative breast cancer. , 2020, The Journal of clinical investigation.

[13]  Maohui Luo,et al.  ZMYND8 Expression in Breast Cancer Cells Blocks T-Lymphocyte Surveillance to Promote Tumor Growth , 2020, Cancer Research.

[14]  A. Harris,et al.  HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer. , 2020, The Journal of clinical investigation.

[15]  Yijie Wang,et al.  CHD4 Promotes Breast Cancer Progression as a Coactivator of Hypoxia-Inducible Factors , 2020, Cancer Research.

[16]  X. Zhang,et al.  EZH2-mediated Epigenetic Silencing of miR-29/miR-30 targets LOXL4 and contributes to Tumorigenesis, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer , 2020, Theranostics.

[17]  B. Haibe-Kains,et al.  Epigenetic switch-induced viral mimicry evasion in chemotherapy resistant breast cancer. , 2020, Cancer discovery.

[18]  S. Raza,et al.  Epigenetic Reprogramming of Cancer-Associated Fibroblasts Deregulates Glucose Metabolism and Facilitates Progression of Breast Cancer. , 2020, Cell reports.

[19]  G. Semenza,et al.  Chemotherapy-induced S100A10 recruits KDM6A to facilitate OCT4-mediated breast cancer stemness. , 2020, The Journal of clinical investigation.

[20]  C. Arteaga,et al.  Overcoming Endocrine Resistance in Breast Cancer. , 2020, Cancer cell.

[21]  Deepak Kgk,et al.  Tumor Microenvironment: Challenges and Opportunities in Targeting Metastasis of Triple Negative Breast Cancer. , 2020, Pharmacological research.

[22]  Cathryn M. Gould,et al.  Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer , 2020, Nature Communications.

[23]  M. Rosemann,et al.  A novel epigenetic signature for overall survival prediction in patients with breast cancer , 2019, Journal of Translational Medicine.

[24]  H. van Attikum,et al.  PHF2 regulates homology-directed DNA repair by controlling the resection of DNA double strand breaks , 2019, bioRxiv.

[25]  Weidong Zhang,et al.  Cardamonin inhibits breast cancer growth by repressing HIF-1α-dependent metabolic reprogramming , 2019, Journal of Experimental & Clinical Cancer Research.

[26]  Weidong Zhang,et al.  Cardamonin inhibits breast cancer growth by repressing HIF-1α-dependent metabolic reprogramming , 2019, Journal of experimental & clinical cancer research : CR.

[27]  Chia-Lang Hsu,et al.  Phf6-null hematopoietic stem cells have enhanced self-renewal capacity and oncogenic potentials. , 2019, Blood advances.

[28]  G. Furtado,et al.  Epidrugs: targeting epigenetic marks in cancer treatment , 2019, Epigenetics.

[29]  Libo Yin,et al.  Downregulation of PHF6 Inhibits Cell Proliferation and Migration in Hepatocellular Carcinoma. , 2019, Cancer biotherapy & radiopharmaceuticals.

[30]  L. Larue,et al.  Chromatin remodellers Brg1 and Bptf are required for normal gene expression and progression of oncogenic Braf-driven mouse melanoma , 2019, Cell Death & Differentiation.

[31]  F. Su,et al.  Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells , 2019, Nature Cell Biology.

[32]  Ming Liu,et al.  Circular RNA circ-DONSON facilitates gastric cancer growth and invasion via NURF complex dependent activation of transcription factor SOX4 , 2019, Molecular cancer.

[33]  Shannon M. White,et al.  The complex entanglement of Hippo-Yap/Taz signaling in tumor immunity , 2019, Oncogene.

[34]  M. Loh,et al.  Phf6 Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL. , 2018, Cancer discovery.

[35]  Xiaodong Zhang,et al.  Yes-associated protein (YAP) binds to HIF-1α and sustains HIF-1α protein stability to promote hepatocellular carcinoma cell glycolysis under hypoxic stress , 2018, Journal of experimental & clinical cancer research : CR.

[36]  W. Luo,et al.  ZMYND8 acetylation mediates HIF-dependent breast cancer progression and metastasis , 2018, The Journal of clinical investigation.

[37]  Hans Clevers,et al.  A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity , 2018, Cell.

[38]  S. Chakravarty,et al.  Characteristics of a PHD Finger Subtype. , 2018, Biochemistry.

[39]  Patrick C. Brennan,et al.  Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence , 2016, Breast Cancer Research and Treatment.

[40]  So Yeon Kwon,et al.  Genome-Wide Mapping Targets of the Metazoan Chromatin Remodeling Factor NURF Reveals Nucleosome Remodeling at Enhancers, Core Promoters and Gene Insulators , 2016, PLoS genetics.

[41]  J. Tyson,et al.  Endocrine resistance in breast cancer – An overview and update , 2015, Molecular and Cellular Endocrinology.

[42]  M. Lustberg,et al.  Endocrine therapy in breast cancer: the neoadjuvant, adjuvant, and metastatic approach. , 2015, Seminars in oncology nursing.

[43]  M. D'Esposito,et al.  Epigenetic control of hypoxia inducible factor-1α-dependent expression of placental growth factor in hypoxic conditions , 2014, Epigenetics.

[44]  David M. Thomas,et al.  The Hippo pathway and human cancer , 2013, Nature Reviews Cancer.

[45]  H. Iwase,et al.  [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[46]  H J Wilson,et al.  An initial evaluation of faults in commercially manufactured crowns. , 1986, Quintessence of dental technology.